Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research

Published: Wednesday, July 04, 2012
Last Updated: Wednesday, July 04, 2012
Bookmark and Share
Dr. Dixon will report directly to Dr. Bharat Chowrira, CEO of Addex, and will be responsible for leading all aspects of research and non-clinical development activities at Addex.

"We are delighted to have Graham join the Addex team. Graham has a strong background and an impressive track record in small molecule pharmaceutical research and development. He has been responsible for the discovery of novel drugs and steering their development from basic science into clinical development, as well as bringing products through mid-stage proof-of-concept clinical trials." stated Dr. Bharat Chowrira, CEO of Addex. "Addex' strength lies in our leading allosteric modulation technology and the ability to leverage this platform to develop drug candidates against previously undruggable but important validated biological targets. Graham's experience and R&D leadership will be instrumental as we execute on our core strategy and continue to build a robust proprietary pipeline of high value drug discovery and development programs and rapidly advancing these drug candidates towards the clinic"

Dr. Dixon joins Addex with more than 20 years of experience in pharmaceutical researc, most recently as Chief Scientific Officer at Galapagos NV. In this role, Dr. Dixon was responsible for all research & early development within the company in multiple therapeutic areas as well as the management of more than 260 scientific personnel across three sites in the Netherlands, Belgium and France. Prior to Galapagos, Dr. Dixon was Chief Scientific Officer at Entomed SA, a developer of natural anticancer and anti-infective agents. Dr. Dixon joined Entomed from a similar role at antifungal therapeutic company, F2G Ltd. Before joining F2G, Dr. Dixon held several roles at AstraZeneca starting as a project manager in anti-infective research and culminating in the role of Global Product Director in the oncology division. He started his career as Head of Biochemistry at Dowelanco (UK) Ltd. Dr. Dixon earned his PhD in biochemistry from the University of Swansea and a BSc in applied biology from the University of Bradford.

"I am excited about joining Addex, the recognized industry leader in allosteric modulation-based oral small molecule drug discovery and development," said Dr. Dixon. "I look forward to building on the significant progress made by the world-class scientists at Addex and applying this powerful platform towards creating an attractive engine of innovative product candidates for the treatment of serious diseases and indications with a huge unmet medical need."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!